<DOC>
	<DOCNO>NCT01532128</DOCNO>
	<brief_summary>The purpose study investigate effect BIA 9-1067 rasagiline pharmacokinetics healthy subject .</brief_summary>
	<brief_title>Effect BIA 9-1067 Rasagiline Pharmacokinetics</brief_title>
	<detailed_description>Single-centre , open-label , randomised , three-way crossover study consist 3 single-dose period separate washout 14 day</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<criteria>Subjects able willing give write informed consent . Male female subject age 18 45 year , inclusive . Subjects body mass index ( BMI ) 18.0 30.0 kg/m2 , inclusive . Subjects healthy determine prestudy medical history , physical examination , vital sign , complete neurological examination 12lead ECG . Subjects negative test HBsAg , antiHCVAb HIV1 HIV2 Ab screen Subjects clinical laboratory test result clinically acceptable screen admission treatment period . Subjects negative screen alcohol drug abuse screen admission treatment period . Subjects nonsmokers exsmokers least 3 month . ( If female ) She childbearing potential reason surgery , childbearing potential , use one follow method contraception : double barrier intrauterine device . ( If female ) She negative pregnancy test ( Î²HCG ) screen admission treatment period . Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , endocrine , connective tissue diseases disorder . Subjects clinically relevant surgical history . Subjects significant abnormality coagulation test . Subjects significant abnormality liver function test ( casebycase decision abnormality discuss Sponsor inclusion ) . Subjects history relevant atopy drug hypersensitivity . Subjects history alcoholism drug abuse . Subjects consume 14 unit alcohol week . Subjects significant infection know inflammatory process screen admission treatment period . Subjects acute gastrointestinal symptom ( e.g. , nausea , vomit , diarrhoea , heartburn ) time screen admission treatment period . Subjects receive fluoxetine within 5 week admission first period . Subjects use medicine within 2 week admission first period could affect safety study assessment , investigator 's opinion . Subjects previously receive BIA 91067 . Subjects use investigational drug participate clinical trial within 90 day prior screen . Subjects donate received blood blood product within 3 month prior screen . Subjects vegetarian , vegan medical dietary restriction . Subjects could communicate reliably investigator . Subjects unlikely cooperate requirement study . Subjects unwilling unable give write informed consent . ( If female ) She pregnant breastfeeding . ( If female ) She childbearing potential use approve effective contraceptive method ( doublebarrier , intrauterine device ) use oral contraceptive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Parkinson Disease</keyword>
	<keyword>BIA 9-1067</keyword>
</DOC>